In the constant quest to enhance the safety and efficacy of pharmaceuticals, a team of researchers from Stanford Medicine has made a remarkable breakthrough that could redefine how drugs are delivered within the body. Their innovative approach harnesses ultrasound-sensitive nanoparticles capable of releasing medications precisely where needed, thus drastically reducing the common problem of off-target side effects that plague many treatments today. This non-invasive technology promises to precision-target drugs with millimeter accuracy, opening new avenues in treatment protocols for conditions ranging from psychiatric disorders to chronic pain.
Traditional medication delivery often suffers from systemic distribution, causing drugs to travel widely throughout the body and interact with unintended tissues, thus triggering undesirable side effects. Psychiatric drugs, for example, might induce dissociation, while painkillers can cause nausea, and chemotherapy typically damages healthy cells along with malignant ones. The novel system developed by the Stanford team encapsulates drugs inside nanoparticles that respond specifically to externally applied ultrasound waves. These waves non-invasively trigger drug release only at targeted sites, offering a level of control and precision unachievable by current methods.
Central to this technology are liposomal nanoparticles—microscopic vesicles with a phospholipid shell—that house the drug in a liquid core. This design draws inspiration from the same kind of nanoparticles used in mRNA COVID-19 vaccines, a nod to the ongoing revolution in nanoparticle production methodologies. The new formulation is not only safer and more stable than previous versions but also easier and more scalable to produce, a crucial factor for potential clinical translation and widespread adoption.
One of the most surprising discoveries is the vital role of a simple kitchen ingredient: sugar. By entrapping a 5% sucrose solution inside the nanoparticle core, the researchers achieved an optimal acoustic contrast necessary for ultrasound detection and activation. This added sucrose increased the density and viscosity of the nanoparticle’s core, creating a subtle but critical difference in acoustic impedance compared to the surrounding tissues. Such contrast ensures that upon ultrasound exposure, the particles resonate and undergo mechanical oscillations, facilitating the controlled release of their drug payload precisely where needed.
The underlying mechanism is believed to involve ultrasound-induced oscillations of the nanoparticle surface against the denser liquid core, which forms transient pores allowing the drug to escape. Despite this insight, the exact biophysical interactions remain under investigation, reflecting the complexity of coupling ultrasound physics and nanomedicine. Importantly, the addition of sucrose helps maintain nanoparticle stability at body temperature and minimizes unwanted premature drug leakage, striking a delicate balance essential for practical therapeutic applications.
Experimental studies on rat models demonstrated the precision and efficacy of this delivery system. Ketamine, a psychoactive drug with dissociative side effects, was encapsulated within these sucrose-loaded nanoparticles and administered systemically. Without ultrasound stimulus, the drug distribution in various organs—including the brain, liver, kidneys, spleen, lungs, heart, and spinal cord—was significantly reduced, indicating minimal off-target exposure. When focused ultrasound was applied to specific brain regions, ketamine release spiked locally, delivering about threefold higher concentrations than in untreated areas, thus enabling targeted neuromodulation.
Remarkably, even a modest 30% increase in local ketamine concentrations had a profound impact on rat behavior. Targeting the medial prefrontal cortex, a brain region regulating emotional states, the team observed measurable reductions in anxiety-like behaviors. Rats receiving the ultrasound-triggered ketamine demonstrated increased exploration of the center of an activity box, a classic indicator of reduced stress. This finding underscores the potential of this technology to isolate therapeutic benefits of psychiatric drugs while mitigating their adverse dissociative effects.
Beyond neuropsychiatric applications, the researchers explored localized pain management by encapsulating ropivacaine, a local anesthetic, within their ultrasound-sensitive nanoparticles. Administering this formulation systemically, they applied brief ultrasound pulses to the sciatic nerve of one leg in rats. The result was a rapid and sustained local anesthetic effect lasting over an hour without affecting the contralateral limb. This approach promises a novel, non-invasive means of inducing regional anesthesia, circumventing the discomfort and complications of direct nerve injections currently employed in clinical practice.
The device’s non-invasive nature offers additional patient benefits, potentially transforming how clinicians manage chronic pain and other localized conditions. Instead of injecting anesthetics or neuromodulatory drugs directly at the site of discomfort, clinicians could administer drugs intravenously and utilize focused ultrasound externally to activate drug release only at the pain site. This strategy not only minimizes procedural pain but also significantly reduces systemic exposure and associated side effects.
Clinical translation of this technology is rapidly approaching. Stanford Medicine’s team, having addressed previous limitations such as the use of exotic and unstable components in early nanoparticle versions, is preparing for initial human trials. Their reliance on liposomal nanoparticles—leveraging existing manufacturing infrastructures developed during the COVID-19 pandemic—and the use of biocompatible ingredients like sucrose significantly increase the likelihood of regulatory approval and commercial scalability. The forthcoming trials aim to assess the system’s efficacy in targeting ketamine to modulate emotional aspects of chronic pain, further bridging neuroscience and pain medicine.
This breakthrough arrives after nearly a decade of research led by Raag Airan, MD, PhD, who emphasizes the transformative potential of combining nanotechnology with acoustically controlled drug delivery. The interdisciplinary work integrates expertise in radiology, materials science, pharmacology, and neurobiology to design a platform that could revolutionize drug administration paradigms. By maximizing therapeutic efficacy while minimizing adverse effects, this technology aligns with the broader precision medicine movement, promising personalized, safe, and highly effective treatments.
The innovation transcends specific drugs tested, offering a universal platform adaptable to various pharmacological agents. Any drug that can be encapsulated within the liposomal nanoparticles and is sensitive to ultrasound-triggered release can, in principle, benefit from this advancement. The system’s modularity and adaptability position it as a generalizable solution for myriad medical conditions across different organ systems.
Funding support from leading institutions including the National Institutes of Health and foundations such as the Ford Foundation underscores the significance and potential impact of this work. As researchers delve deeper into optimizing nanoparticle formulations and exploring ultrasound parameters, the promise of safe, targeted, and non-invasive drug delivery inches closer to becoming a clinical reality that could redefine patient care worldwide.
Subject of Research: Animals
Article Title: Acoustically activatable liposomes as a translational nanotechnology for site-targeted drug delivery and noninvasive neuromodulation
News Publication Date: 18-Aug-2025
Web References:
http://dx.doi.org/10.1038/s41565-025-01990-5
Image Credits: Emily Moskal/Stanford Medicine
Keywords: Nanoparticles, Medications
